

HR 2026

Pharmaceutical Information Exchange Act

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 6, 2017

Current Status: Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .

Latest Action: Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 . (Jan 17, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/2026>

Sponsor

Name: Rep. Guthrie, Brett [R-KY-2]

Party: Republican • **State:** KY • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Jan 17, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 6, 2017)

Pharmaceutical Information Exchange Act

This bill amends the Federal Food, Drug, and Cosmetic Act to allow information about a new investigational medication or the investigational use of a medication approved by the Food and Drug Administration to be provided to health care entities if the information is based on reliable scientific evidence.

Actions Timeline

- **Jan 17, 2018:** Subcommittee Consideration and Mark-up Session Held.
- **Jan 17, 2018:** Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .
- **Apr 7, 2017:** Referred to the Subcommittee on Health.
- **Apr 6, 2017:** Introduced in House
- **Apr 6, 2017:** Referred to the House Committee on Energy and Commerce.